CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Short Interest Up 188.2% in March

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the target of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 843,600 shares, an increase of 188.2% from the February 28th total of 292,700 shares. Based on an average daily volume of 685,500 shares, the days-to-cover ratio is presently 1.2 days. Approximately 34.6% of the company’s shares are short sold.

Institutional Investors Weigh In On CERo Therapeutics

A hedge fund recently raised its stake in CERo Therapeutics stock. ARCH Venture Management LLC lifted its position in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) by 550.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,393,561 shares of the company’s stock after purchasing an additional 7,949,265 shares during the period. CERo Therapeutics accounts for about 0.2% of ARCH Venture Management LLC’s investment portfolio, making the stock its 9th biggest position. ARCH Venture Management LLC owned approximately 626.24% of CERo Therapeutics worth $564,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 29.64% of the company’s stock.

CERo Therapeutics Price Performance

Shares of CERO opened at $0.75 on Friday. The firm has a fifty day moving average price of $1.61 and a 200-day moving average price of $7.25. CERo Therapeutics has a 12-month low of $0.66 and a 12-month high of $376.00.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.